| Combined nivolumab and ipilimumab or monotherapy in untreated melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... New England journal of medicine 373 (1), 23-34, 2015 | 8048 | 2015 |
| Pembrolizumab versus ipilimumab in advanced melanoma C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... New England Journal of Medicine 372 (26), 2521-2532, 2015 | 6185 | 2015 |
| Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017 | 3621 | 2017 |
| Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019 | 3170 | 2019 |
| Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ... JAMA oncology 4 (12), 1721-1728, 2018 | 2049 | 2018 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ... New England Journal of Medicine 378 (19), 1789-1801, 2018 | 1800 | 2018 |
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ... The lancet oncology 16 (8), 908-918, 2015 | 1768 | 2015 |
| Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet 390 (10105), 1853-1862, 2017 | 1299 | 2017 |
| Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709-717, 2017 | 1080 | 2017 |
| Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet Oncology 20 (9), 1239-1251, 2019 | 1050 | 2019 |
| Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ... Annals of Oncology 28 (2), 368-376, 2017 | 815 | 2017 |
| Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double … GV Long, R Dummer, O Hamid, TF Gajewski, C Caglevic, S Dalle, ... The Lancet Oncology 20 (8), 1083-1097, 2019 | 701 | 2019 |
| Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ... Journal of Clinical Oncology 40 (2), 127-137, 2022 | 684 | 2022 |
| Immune checkpoint inhibitors in melanoma MS Carlino, J Larkin, GV Long The Lancet 398 (10304), 1002-1014, 2021 | 670 | 2021 |
| Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy TN Gide, C Quek, AM Menzies, AT Tasker, P Shang, J Holst, J Madore, ... Cancer cell 35 (2), 238-255. e6, 2019 | 662 | 2019 |
| Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ... JAMA oncology 2 (2), 234-240, 2016 | 630 | 2016 |
| BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact H Rizos, AM Menzies, GM Pupo, MS Carlino, C Fung, J Hyman, LE Haydu, ... Clinical cancer research 20 (7), 1965-1977, 2014 | 572 | 2014 |
| Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort … JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ... The Lancet Oncology 19 (3), 310-322, 2018 | 553 | 2018 |
| Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma AM Menzies, LE Haydu, L Visintin, MS Carlino, JR Howle, JF Thompson, ... Clinical cancer research 18 (12), 3242-3249, 2012 | 541 | 2012 |
| Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma GV Long, C Fung, AM Menzies, GM Pupo, MS Carlino, J Hyman, ... Nature communications 5 (1), 5694, 2014 | 392 | 2014 |
Georgina V LongMelanoma Institute Australia, The University of Sydney and Royal North Shore Hospital在 sydney.edu.au 的电子邮件经过验证
